Table 2 Correlation analysis between RAE1 and clinicopathological features.

From: The mitotic checkpoint regulator RAE1 induces aggressive breast cancer cell phenotypes by mediating epithelial-mesenchymal transition

 

Allred score 3

Allred score 5

<3

≥3

p-value

<5

≥5

p-value

n = 73

n = 25

n = 82

n = 16

Tumour size

  

0.397

  

0.794

≤2 cm

45 (61.6%)

13 (52.0%)

 

49 (59.8%)

9 (56.3%)

 

>2 cm

28 (38.4%)

12 (48.0%)

 

33 (40.2%)

7 (43.8%)

 

Lymph node

  

0.537

  

1.000

Negative

41 (56.9%)

16 (64.0%)

 

48 (59.3%)

9 (56.3%)

 

Positive

31 (43.1%)

9 (36.0%)

 

33 (40.7%)

7 (43.8%)

 

Unknown

   

1

0

 

Histologic grade

  

0.187

  

0.013

I, II

46 (63.0%)

12 (48.0%)

 

53 (64.6%)

5 (31.3%)

 

III

27 (37.0%)

13 (52.0%)

 

29 (35.4%)

11 (68.8%)

 

Oestrogen receptor

  

0.947

  

0.343

Negative

18 (24.7%)

6 (24.0%)

 

22 (26.8%)

2 (12.5%)

 

Positive

55 (75.3%)

19 (76.0%)

 

60 (73.2%)

14 (87.5%)

 

Progesterone receptor

  

0.469

  

0.865

Negative

29 (39.7%)

12 (48.0%)

 

34 (41.5%)

7 (43.8%)

 

Positive

44 (60.3%)

13 (52.0%)

 

48 (58.5%)

9 (56.3%)

 

HER2

  

0.729

  

0.548

Negative

46 (63.9%)

15 (60.0%)

 

52 (64.2%)

9 (56.3%)

 

Positive

26 (36.1%)

10 (40.0%)

 

29 (35.8%)

7 (43.8%)

 
  1. HER2, human epidermal growth factor receptor 2.
Back to article page